|
Title
|
|
|
|
Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Several noncardiovascular drugs with QT liability are currently on the market. Previous epidemiological studies have shown significant exposure of the general population to drugs with QT liability with similar consumption in many European countries. Several regulatory measures have concerned medicinal products carrying a pro-arrhythmic risk in humans. WHAT THIS STUDY ADDS The list of antibacterial agents with documented QT liability has grown over the last few years. Notwithstanding stringent regulatory measures, population exposure to antibiotics with QT liability is still significant in several countries. The magnitude of the problem is clearly heterogeneous, with remarkable diversity between Northern and Southern countries (lower and higher exposure, respectively). |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
British journal of clinical pharmacology. - London
| |
|
Publication
|
|
|
|
London
:
2008
| |
|
ISSN
|
|
|
|
0306-5251
| |
|
DOI
|
|
|
|
10.1111/J.1365-2125.2008.03319.X
| |
|
Volume/pages
|
|
|
|
67
:1
(2008)
, p. 88-98
| |
|
ISI
|
|
|
|
000263303000012
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|